| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6784197 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(3 years ago) | |
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492416 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(3 years ago) | |
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(5 years from now) | |
Briviact is owned by Ucb Inc.
Briviact contains Brivaracetam.
Briviact has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Briviact are:
- US8492416
- US6784197
Briviact was authorised for market use on 12 May, 2016.
Briviact is available in solution;oral, solution;intravenous, tablet;oral dosage forms.
Briviact can be used as treatment of partial-onset seizures in patients 4 years of age and older.
Drug patent challenges can be filed against Briviact from 12 May, 2020.
The generics of Briviact are possible to be released after 09 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older
Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS
BRIVIACT family patents
